How to decide on the best treatment option for metastatic hormone-sensitive prostate cancer

Talking Oncology

A/Prof Andrew Weickhardt and Dr Ainsley Campbell discuss treatment options for newly diagnosed metastatic prostate cancer, with esteemed guest Professor Ian Davis. Andrew Weickhardt is a consultant medical oncologist with a major interest in genitourinary cancers. Andrew has a joint appointment between Austin Hospital and the Olivia Newton John Cancer Research Institute. He oversees the genitourinary clinical trials program at the Austin Hospital. He has published over 20 peer reviewed publications and his research on targeted therapies has been recognised with multiple awards including two American Society for Clinical Oncology Merit Awards. Ainsley Campbell is a medical oncologist and Director of Genetics at Austin Health based in Heidelberg, Victoria. Ainsley has an interest in GU oncology and cancer genetics. Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University & Eastern Health, in Melbourne Australia. He is an NHMRC Practitioner Fellow. He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, is an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers.